Abstract
Management of dopamine agonist (DA)–resistant prolactinomas that are not responding to second- and third-line treatments is challenging and necessitates alternative medical therapy. The presence of estrogen receptors on pituitary tumors accompanied by the variable behavior of pituitary tumors in the presence of estrogen prompted the study of the role of antiestrogen in the treatment of DA-resistant prolactinomas. The purpose of this paper is to provide a systematic review of the role of tamoxifen in the treatment of prolactin-secreting adenomas resistant to dopamine agonists.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
